Skin Tag Remover Patches

Description

The drug is identified by SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, imprinted with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the removal of plantar warts located on the bottom of the foot. Plantar warts are characterized by their specific location, tenderness, and disruption of the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For the removal of common warts, which are characterized by their rough, 'cauliflower-like' surface appearance, the recommended dosage and administration should be carefully followed.

The treatment should be applied directly to the wart. It is essential to ensure that the area surrounding the wart is protected to prevent irritation. The application may be repeated as necessary, typically at intervals of 1 to 2 weeks, depending on the response to treatment and the specific product used.

Healthcare professionals should instruct patients to monitor the wart for signs of improvement or any adverse reactions. If there is no noticeable change after several applications, or if the wart appears to worsen, further evaluation may be warranted.

Contraindications

The use of this product is contraindicated in the following situations:

• Application on irritated skin or on any area that is infected or reddened, due to the potential for exacerbating the condition.

• Use in patients with diabetes, as they may have compromised healing and increased risk of infection.

• Application in individuals with poor blood circulation, which may hinder proper absorption and increase the risk of adverse effects.

Warnings and Precautions

For products containing any ingredient identified in S MO28.10, it is imperative to adhere to the following warnings and precautions to ensure safe usage.

External Use Only These products are intended for external application only. They must not be applied to irritated skin, infected areas, or any regions exhibiting redness. Additionally, individuals with diabetes or those who have poor blood circulation should refrain from using these products.

Specific Application Restrictions The use of these products is contraindicated on moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes. Should discomfort persist after application, it is essential to consult a healthcare professional.

Flammability Warning Products formulated in a flammable vehicle must include an appropriate flammability signal word on the labeling, such as “extremely flammable,” “flammable,” or “combustible,” in accordance with 16 CFR 1500.3(b)(10). Users should exercise caution and keep these products away from fire or flame to prevent potential hazards.

In summary, adherence to these warnings and precautions is crucial for the safe use of these products. Healthcare professionals should ensure that patients are informed of these guidelines to mitigate risks associated with their use.

Side Effects

Patients using products containing any ingredient identified in S MO28.10 should be aware that these products are for external use only. They must not be applied to irritated skin, infected or reddened areas, or on individuals who are diabetic or have poor blood circulation. If discomfort persists after application, patients are advised to consult their healthcare provider. Additionally, these products should not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

For products formulated in a flammable vehicle, it is essential that the labeling includes an appropriate flammability signal word, such as “extremely flammable,” “flammable,” or “combustible,” in accordance with 16 CFR 1500.3(b)(10). Patients should take precautions to keep these products away from fire or flame to prevent any potential hazards.

Drug Interactions

There are no reported drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Skin Tag Remover Patches (salicylic acid 5%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should not be exposed to this product, as it is advised to keep it out of reach of children. The product is contraindicated for use on irritated skin or any area that is infected or reddened. Additionally, it should not be used by individuals with diabetes or those who have poor blood circulation. Caution is warranted when considering the use of this product in pediatric populations.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions that should be taken. Healthcare professionals are advised to consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in consultation with the patient. Women of childbearing potential should be informed of the absence of established safety data during pregnancy.

Lactation

There is no specific information regarding the use of SKIN TAG REMOVER PATCHES (salicylic acid 5% patch) in lactating mothers or lactation considerations. The effects on breastfed infants and the excretion of salicylic acid in breast milk have not been established. Therefore, healthcare professionals should exercise caution when recommending this product to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution and consider individual patient factors when prescribing to patients with reduced kidney function, as the absence of specific guidance necessitates careful clinical judgment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide further management and treatment options.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this product out of the reach of children to prevent accidental ingestion or misuse.

Patients should be instructed not to use this product on irritated skin or on any area that is infected or reddened. Additionally, it is important to inform patients that individuals with diabetes or those who have poor blood circulation should avoid using this product due to potential complications.

Storage and Handling

The product is supplied in a configuration that ensures optimal handling and storage. It should be stored at room temperature, away from direct sunlight and moisture. To maintain safety, it is essential to keep the product out of reach of children.

Special handling precautions include avoiding application on irritated skin or any areas that are infected or reddened. Additionally, the product must be kept away from fire or flame to prevent any hazardous situations.

Additional Clinical Information

The route of administration for the product is topical. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Skin Tag Remover Patches, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)